Meloxicam Market size is anticipated to reach USD 47 billion by the end of 2036, expanding around 5% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of meloxicam was over USD 7 billion. The growth of this market can be attributed to the back of increasing prevalence of osteoarthritis, juvenile rheumatoid arthritis, and rheumatoid arthritis especially among the old population. Meloxicam is an effective pain management medication highly used in the treatment of the above health problems. In this health issue when doctors initiate surgeries the post-surgery pain is always at a high range and is too much painful in order to offer relief from this pain to patients doctors use pain management medications such as meloxicam. Thus, the increasing incidence of these diseases is raising the demand for meloxicam market in the projected time period. As per a report by the World Health Organization, 60% of those who have osteoarthritis are female and 73% are older than 55. The knee is the joint that is most frequently affected, with an estimated number of 365 million, next to the hip and the hand.
Furthermore, the growth of the market can also be driven by increasing awareness about the availability of pain relief medication. In the past few times, there has been a surge in awareness about pain relief medication available in the market among the population. This is predicted to boost the market growth of meloxicam in the projection time period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 - 2036 |
|
CAGR |
~5% |
|
Base Year Market Size |
~USD 7 billion |
|
Forecast Year Market Size |
~USD 47 billion |
|
Regional Scope |
|
Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis)
In terms of disease, the osteoarthritis segment in the meloxicam market is estimated to account for the largest revenue share of 40% by the end of 2036. The rise in prevalence and consumer awareness of treatment options like glucosamine and chondroitin sulfate, which do not significantly reduce the signs of this medical condition but instead assist in preserving joint motion over an extended period of time, can be attributed to the growth of this market in the projected time period. A severe health emergency also includes arthritis. According to the CDC, 53.2 million US individuals, or 1 in 4, have some kind of arthritis. There are more than 100 different forms of arthritis, but osteoarthritis, which affects 32.5 million US adults, is the most widespread.
Drug Type (Combination Drug, Prescribed Drug)
Meloxicam market from the combination drug segment is set to grow significantly by 2036. Combination drugs are drugs taken together to treat different conditions, and their ability to treat many diseases is the main reason for this increase in demand. For example, Vioxx is a combination drug used to treat both rheumatoid arthritis and pain; however, it caused heart problems as well as other side effects and thus fell behind in the market.
Our in-depth analysis of the global meloxicam market includes the following segments:
|
Diseases |
|
|
Drug Type |
|
|
Population Type |
|
|
Dosage |
|
|
Dose Strength |
|
|
End-Users |
|
|
Distribution Channel |
|
North American Market Forecasts
The meloxicam market in North America region is anticipated to account for the largest revenue share of 33% by the end of the forecast period. The growth of this market can be primarily driven by an increasing number of arthritis and other chronic pain disease patients found in this region. Besides, increasing healthcare infrastructure and escalating research and development activities in meloxicam are driving the market expansion further in the North America region during the projected period. An estimated 58.5 million US adults have been told by their doctor that they have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia, based on data from the National Health Interview Survey between 2016 and 2018.
APAC Market Statistics
The meloxicam market in the Asia Pacific region is estimated to account for a notable revenue share during the forecast period. This growth can be attributed to high product demand due to the growing aging population and the increasing incidence of osteoarthritis, rheumatoid arthritis, soft tissue inflammation, traumatic pain and post-operative pain. Also, there has been surging demand for rheumatoid arthritis treatment in the region. Additionally, regional growth over the forecast period is expected to be driven by favorable reimbursement policies for generic drugs. All these factors are predicted to drive the market growth of meloxicam in the APAC region during the studied period.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?